Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.H Lundbeck, a pharmaceutical company, has announced the availability of Onfi tablets for prescribing in the US.
Subscribe to our email newsletter
The FDA approved Onfi for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.
Onfi is an oral anti-epileptic drug (AED) of the benzodiazepine class, and is a 1,5 benzodiazepine.
Onfi is a federally controlled schedule four substance (C-IV), the company said.
Lundbeck commercial operations executive vice president Marie-Laure Pochon said that Onfi has in clinical studies shown to be an effective add-on therapy for seizures associated with LGS.